Asset Details
Do you wish to reserve the book?
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Do you wish to request the book?
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
2016
Overview
Key Points
Osteoarthritis (OA) represents the failure of the joint as an organ
Synovitis is increasingly recognized as a characteristic of the OA joint, and its presence is associated with increased severity of symptoms, joint dysfunction, and cartilage loss
Studies in humans and animal models demonstrate a key role for chronic, low-grade inflammation in the pathogenesis of OA
Innate immune pathways, such as the complement and pattern-recognition receptor pathways, are pivotal to the inflammation in OA
Clinical trials are needed to determine whether anti-inflammatory therapeutics can prevent or slow disease progression in OA
Emerging evidence indicates that the inflammatory mechanisms involved in the pathophysiology of osteoarthritis (OA) differ from those in rheumatoid arthritis. This Review explores the mechanisms of chronic, low-grade inflammation in OA, discusses the evidence of their central role in its pathogenesis, and explores how they might be targeted to prevent or treat OA.
Osteoarthritis (OA) has long been viewed as a degenerative disease of cartilage, but accumulating evidence indicates that inflammation has a critical role in its pathogenesis. Furthermore, we now appreciate that OA pathogenesis involves not only breakdown of cartilage, but also remodelling of the underlying bone, formation of ectopic bone, hypertrophy of the joint capsule, and inflammation of the synovial lining. That is, OA is a disorder of the joint as a whole, with inflammation driving many pathologic changes. The inflammation in OA is distinct from that in rheumatoid arthritis and other autoimmune diseases: it is chronic, comparatively low-grade, and mediated primarily by the innate immune system. Current treatments for OA only control the symptoms, and none has been FDA-approved for the prevention or slowing of disease progression. However, increasing insight into the inflammatory underpinnings of OA holds promise for the development of new, disease-modifying therapies. Indeed, several anti-inflammatory therapies have shown promise in animal models of OA. Further work is needed to identify effective inhibitors of the low-grade inflammation in OA, and to determine whether therapies that target this inflammation can prevent or slow the development and progression of the disease.
Publisher
Nature Publishing Group UK,Nature Publishing Group
